

# ***TERT* promoter mutations are rare in bone and soft tissue sarcomas of Japanese patients**

TSUYOSHI SAITO<sup>1</sup>, KEISUKE AKAIKE<sup>1,2</sup>, AIKO KURISAKI-ARAKAWA<sup>1</sup>, MIDORI TODA-ISHII<sup>1,2</sup>, KENTA MUKAIHARA<sup>1,2</sup>, YOSHIYUKI SUEHARA<sup>2</sup>, TATSUYA TAKAGI<sup>2</sup>, KAZUO KANEKO<sup>2</sup> and TAKASHI YAO<sup>1</sup>

Departments of <sup>1</sup>Human Pathology and <sup>2</sup>Orthopaedic Surgery, Juntendo University School of Medicine, Tokyo 113-8421, Japan

Received July 8, 2015; Accepted October 21, 2015

DOI: 10.3892/mco.2015.674

**Abstract.** Recurrent hot-spot mutations in the telomerase reverse transcriptase (*TERT*) promoter have been reported in various types of tumor. In several tumor types, *TERT* promoter mutations are associated with poor clinical outcomes. *TERT* promoter mutations are reported to be rare in soft tissue tumors, with the exception of myxoid liposarcoma (MLS). Our previous study reported that *TERT* promoter mutations occurred in a subset of solitary fibrous tumors (SFTs) and were associated with adverse clinical outcomes in Japanese individuals. The site-specific frequency (e.g. central nervous or soft tissue origin) of *TERT* promoter mutations in our SFT cases appeared to be different from previously reported values in a European population. These findings prompted the present study to elucidate the potential role of ethnic background in the different frequencies of *TERT* promoter mutations in bone and soft tissue sarcomas. In the present study, *TERT* promoter mutations were examined in 180 cases of bone and soft tissue sarcomas. *TERT* promoter region mutations were identified in 10 cases [5 SFTs, 3 MLSs, 1 undifferentiated pleomorphic sarcoma (UPS) and 1 malignant granular cell tumor]. All mutations were C228T. The frequencies of *TERT* promoter mutation in MLS and UPS were 23.1 (3/13) and 5% (1/20), respectively. Only 1/5 patients with *TERT*-mutated tumors experienced local recurrence or distant metastasis. The present study revealed the first case of a malignant granular cell tumor with a *TERT* promoter mutation and revealed that the frequency of *TERT* promoter mutations in MLSs of Japanese patients is lower compared with that reported in German patients, providing evidence of a possible ethnic difference in the frequency of *TERT* promoter mutations.

## **Introduction**

Telomere activity is associated with malignant potential in neoplasia (1). The ability to maintain telomere length is a typical feature in neoplasia and previous studies have revealed the robust expression of telomerase reverse transcriptase (*TERT*) in numerous human malignancies (2,3). Recurrent hot-spot mutations in the *TERT* promoter were initially reported in melanoma (4,5) and subsequently in various tumor types, including primary nervous system tumors (6). Two hot-spot mutations, C228T and C250T, create novel binding sites for E-twenty-six (ETS) transcription factors, resulting in a maximum 4- to 5-fold increase in the induction of the *TERT* gene (4,5). Previous studies also demonstrated that *TERT* promoter mutations occur in ~50% of SFTs of central nervous system (CNS) origin (6). However, with the exception of myxoid liposarcomas (MLSs), *TERT* promoter mutations are relatively rare in soft tissue sarcomas, including SFTs (7). Our previous study reported that *TERT* promoter mutations are associated with poor clinical outcomes in SFT in Japanese individuals (8). However, the tumor site-specific frequency of *TERT* promoter mutations in our SFT cases (8) appeared to be different from previously reported values (6,7). These findings prompted the present study to elucidate the potential role of ethnic background in the possibly different frequencies of *TERT* promoter mutations in bone and soft tissue sarcomas.

In the present study, *TERT* promoter mutations were examined in 180 cases of bone and soft tissue sarcomas to elucidate its frequency in Japanese patients. It was demonstrated that *TERT* promoter mutation rates in MLSs of Japanese patients were lower compared with the reported values in German patients.

## **Materials and methods**

*Sample preparation.* The sarcoma tissue samples were collected from the pathology records at the Pathology Division of Juntendo University Hospital (Tokyo, Japan), which were surgically resected between April 1990 and March 2010 at Juntendo University Hospital. Diagnoses were made based on the standard histopathological criteria in conjunction with immunohistochemical and molecular analysis, according to the current World Health Organization classification (9). In total, 180 cases of bone and soft tissue sarcomas were

---

*Correspondence to:* Dr Tsuyoshi Saito, Department of Human Pathology, Juntendo University School of Medicine, 2-1-1 Hongo, Bunkyo-ku, Tokyo 113-8421, Japan  
E-mail: taysaitou@juntendo.ac.jp

**Key words:** *TERT*, mutation, bone and soft tissue sarcoma

included in the present study. Among these 180 cases, data regarding 40 SFT cases were from our previous study (8). In addition, 3 cases of lipoblastoma and 5 cases of granular cell tumor of soft tissue origin were also collected for comparison. The numbers and types of bone and soft tissue tumors used in the present study are summarized in Table I.

**Ethics approval.** This study was approved by the research Ethics Committee of Juntendo University, School of Medicine (Tokyo, Japan). Written informed consent was obtained from the patients.

**Mutational analysis of the *TERT* promoter.** The genomic DNA was extracted from each formalin-fixed, paraffin-embedded tissue block. When isolating DNA, the most representative tissue blocks, containing the maximum percentage of tumor tissue were selected. The surrounding non-tumoral tissues were manually removed by dissection to enrich the percentage of tumor cells. The *TERT* promoter region mutations were examined using polymerase chain reaction (PCR), followed by direct sequencing with previously described primer pairs (6). The AccuPrime™ GC-rich DNA polymerase kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used for PCR. The PCR products were electrophoresed in a 2% agarose gel and were recovered using the QIAquick Gel Extraction kit (Qiagen, Hilden, Germany). Isolated PCR products were subsequently sequenced using a capillary sequencing machine 202 (3730xl Genetic Analyzer; Applied Biosystems) in the sense and antisense directions, and were analyzed by Sequencing Analysis V3.5.1 software (Applied Biosystems; Thermo Fisher Scientific, Inc.). Once mutations were detected, the corresponding non-tumoral DNA were also extracted to confirm the obtained mutations as tumor-specific mutations.

## Results

*TERT* promoter region mutations were identified in 10 cases [5 SFTs, 3 MLSs (Fig. 1), 1 pleomorphic sarcoma and 1 malignant granular cell tumor]. These mutations were confirmed as tumor-specific mutations. The clinicopathological data of cases with *TERT* promoter mutations are summarized in Table II. All mutations were C228T. The frequencies of *TERT* promoter mutation in MLS and pleomorphic undifferentiated sarcoma were 23.1 (3/13) and 5% (1/20), respectively. It was demonstrated that 2/3 MLSs with a *TERT* promoter mutation contained areas with a round-cell component. It was recently reported that *TERT* promoter mutations were associated with an adverse clinical course in SFTs (8), therefore, the prognostic impact of *TERT* promoter mutations in these tumors was also assessed. However, 4/5 patients with *TERT*-mutated tumors experienced no local recurrence or distant metastasis. Only 1 patient with *TERT*-mutated pleomorphic sarcoma experienced lung metastasis 46 months following the wide resection of the tumor and subsequently underwent a resection of the metastasized tumor. This patient survived and currently exhibits no evidence of the disease. Furthermore, *TERT* promoter mutations were detected in 1/2 patients with malignant granular cell tumor, although it was not observed in any of 5 granular cell tumors.

Table I. Examination *TERT* mutations of bone and soft tissue tumors.

Tumor type	<i>TERT</i> mutations (no. cases)
Soft tissue sarcomas	
Myxoid liposarcoma	3 (13)
Well differentiated liposarcoma	0 (18)
Myxofibrosarcoma	0 (6)
Pleomorphic undifferentiated sarcoma	1 (20)
Leiomyosarcoma	0 (19)
Pleomorphic leiomyosarcoma	0 (5)
Rhabdomyosarcoma	0 (5)
Synovial sarcoma	0 (7)
Dermatofibrosarcoma protuberans	0 (6)
Ewing/primitive neuroectodermal tumor	0 (6)
Alveolar soft part sarcoma	0 (3)
Malignant peripheral nerve sheath tumor	0 (1)
Extraskelatal myxoid chondrosarcoma	0 (1)
Clear cell sarcoma	0 (1)
Endometrial stromal sarcoma	0 (1)
Malignant granular cell tumor	1 (2)
Solitary fibrous tumor	5 (40)
Total	10 (154)
Bone sarcomas	
Osteosarcoma	0 (14)
Chondrosarcoma	0 (10)
Malignant fibrous histiocytoma of bone	0 (2)
Total	0 (26)
Benign tumors (control)	
Lipoblastoma	0 (3)
Granular cell tumor	0 (5)

*TERT*, telomerase reverse transcriptase.

Other mutations neighboring the hot-spots were also noted in 3 cases, C229T in a case of synovial sarcoma, C230T in a case of myxofibrosarcoma and C232T in a case of Ewing/primitive neuroectodermal tumor, however, these mutations generated no consensus binding sites for ETS transcription factors within the *TERT* promoter region (10).

## Discussion

Telomeres are extended by the protein complex, telomerase, in which the enzyme *TERT* exerts a pivotal role (11). *TERT* promoter hot-spot mutations recently emerged as an underlying mechanism of *TERT* upregulation in certain human cancer types. In SFTs of the CNS, *TERT* promoter mutations were identified in 50% of cases (6). However, in our previous study, *TERT* promoter mutations were detected in 5/40 SFTs (12.5%, 0/6 of CNS origin, 2/25 of pleural/lung origin and 3/9 of soft tissue origin (8). However, another previous study reported that *TERT* promoter mutations were observed in 4/31 (13%) SFTs of soft tissue origin (7). These findings

Table II. Clinical information of tumors with *TERT* mutations.

Case	Age/sex	Location	Diagnosis	Mutation	Treatment	Prognosis
96	47/F	R. lower leg	Myxoid liposarcoma with RC	C228T	CTx+WR+CTx	NED (58 mos)
276	58/M	R. thigh	Malignant granular cell tumor	C228T	WR	NED (72 mos)
278	60/M	R. thigh	Pleomorphic sarcoma	C228T	WR	Lung metastasis (46 mos) Alive with NED (103 mos)
280	56/M	R. thigh	Myxoid liposarcoma	C228T	WR+RTx	NED (61 mos)
370	43/M	L. thigh	Myxoid liposarcoma with RC	C228T	WR+CTx	NED (43 mos)

*TERT*, telomerase reverse transcriptase; F, female; M, male; R, right; L, left; RC, round cell; CTx, chemotherapy; WR, wide resection; RTx, radiation therapy NED; no evidence of disease.




Figure 1. Telomerase reverse transcriptase gene promoter mutation in a case of myxoid liposarcoma (Case 96). The representative chromatogram shows a heterozygous C228T mutation.

appear to be at odds and prompted the present study to investigate if a difference in ethnic background may contribute to this discrepancy. In the present study, a *TERT* promoter mutation in MLS was detected in 3/13 cases (23.1%), which is lower compared with a previously reported value of 74% in this tumor type (7). The sensitivity of the examination may affect the lower frequency of *TERT* promoter mutation, however, the present study attempted to enrich the quantities of tumor cells during DNA isolation. These findings supported the present hypothesis that ethnic differences may affect the frequency of *TERT* promoter mutations.

In the present study, 2/3 MLSs with *TERT* promoter mutations contained a round-cell component, however, there was no association between *TERT* promoter mutation and the presence of a round-cell component, consistent with previous findings (7).

Lipoblastoma is a benign lipogenic tumor arising in infants and younger children. The histology of lipoblastoma overlaps with other lipomatous tumors, including MLSs, therefore, the frequency of *TERT* promoter mutations was assessed in lipoblastomas. However, 0/3 cases of this tumor type harbored a *TERT* promoter mutation.

Granular cell tumor is a benign Schwann cell lesion and typically occurs in the skin and subcutis. The clinical and morphological criteria for malignant granular cell tumor is well described (12). In the present study, 2 cases of malignant granular cell tumors were included. The clinical course in one was previously reported in detail (13), although it was the other case, which harbored the *TERT* promoter mutation. Genetic alterations in malignant granular cell tumors remain

to be described in detail, however, it has been reported that a malignant granular cell tumor is characterized by a gain of chromosome 10 and a loss of p16 (14). Another previous report shows that malignant granular cell tumors share certain cytogenetic abnormalities with malignant peripheral nerve sheath tumors (MPNSTs), leading to the hypothesis that they may represent histogenetically associated lesions (15). The present study identified a *TERT* promoter mutation in 1/2 malignant granular cell tumor cases, however, not in a sporadic MPNST case. A previous study demonstrated that the *TERT* promoter mutation is also rare in sporadic MPNSTs and absent in neurofibromatosis type 1-associated MPNSTs (16), although another previous study revealed that *TERT* promoter hot-spot mutations were observed in 6% of MPNSTs (7). The present study cannot comment on the hypothesis of histogenetic similarity between malignant granular cell tumors and MPNSTs, since the present study included only a few cases of these tumor types. However, although malignant granular cell tumors are relatively rare, it is of interest to further investigate the frequency of *TERT* promoter mutations in malignant granular cell tumors to elucidate the association between *TERT* promoter mutations and the malignant behavior of this tumor. *TERT* promoter mutations in this tumor type may be in part driven by its presence in the dermal or subcutaneous localization, since this type of C to T alteration is a ultraviolet signature mutation, and *TERT* promoter mutations are frequently observed in atypical fibroxanthomas and pleomorphic dermal sarcomas (17).

In conclusion, the present study revealed the first case, to the best of our knowledge, of malignant granular cell tumor

with a *TERT* promoter mutation and demonstrated that the frequency of *TERT* promoter mutations in MLSs of Japanese patients is lower compared with that reported in German patients.

### Acknowledgements

The present study was supported, in part, by a Grant-in-Aid for General Scientific Research from the Ministry of Education, Science, Sports and Culture, Tokyo, Japan (grant no. 26670286).

### References

1. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimasic T, Ghossein RA and Fagin JA: Frequent somatic *TERT* promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. *J Clin Endocrinol Metab* 98: E1562-E1566, 2013.
2. Shay JW and Bacchetti S: A survey of telomerase activity in human cancer. *Eur J Cancer* 33: 787-791, 1997.
3. Ulaner GA, Hoffman AR, Otero J, Huang HY, Zhao Z, Mazumdar M, Gorlick R, Meyers P, Healey JH and Ladanyi M: Divergent patterns of telomere maintenance mechanisms among human sarcomas: Sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. *Genes Chromosomes Cancer* 41: 155-162, 2004.
4. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, *et al*: *TERT* promoter mutations in familial and sporadic melanoma. *Science* 339: 959-961, 2013.
5. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L and Garraway LA: Highly recurrent *TERT* promoter mutations in human melanoma. *Science* 339: 957-959, 2013.
6. Koelsche C, Sahm F, Capper D, Reuss D, Sturm D, Jones DT, Kool M, Northcott PA, Wiestler B, Böhmer K, *et al*: Distribution of *TERT* promoter mutations in pediatric and adult tumors of the nervous system. *Acta Neuropathol* 126: 907-915, 2013.
7. Koelsche C, Renner M, Hartmann W, Brandt R, Lehner B, Waldburger N, Alldinger I, Schmitt T, Egerer G, Penzel R, *et al*: *TERT* promoter hotspot mutations are recurrent in myxoid liposarcomas but rare in other soft tissue sarcoma entities. *J Exp Clin Cancer Res* 33: 33, 2014.
8. Akaike K, Kurisaki-Arakawa A, Hara K, Suehara Y, Takagi T, Mitani K, Kaneko K, Yao T and Saito T: Distinct clinicopathological features of NAB2-STAT6 fusion gene variants in solitary fibrous tumor with emphasis on the acquisition of highly malignant potential. *Hum Pathol* 46: 347-356, 2015.
9. Fletcher CDM, Bridge JA, Hogendoorn PCW and Mertens F (eds): World Health Organization (WHO) Classification of Tumours of Soft Tissue. World Health Organization International Agency for Research on Cancer. IARC Press, Lyon, 2013.
10. Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D and Cech TR: Cancer. *TERT* promoter mutations and telomerase reactivation in urothelial cancer. *Science* 347: 1006-1010, 2015.
11. Xu L, Li S and Stohr BA: The role of telomere biology in cancer. *Annu Rev Pathol* 8: 49-78, 2013.
12. Fanburg-Smith JC, Meis-Kindblom JM, Fante R and Kindblom LG: Malignant granular cell tumor of soft tissue: Diagnostic criteria and clinicopathologic correlation. *Am J Surg Pathol* 22: 779-794, 1998.
13. Saito T, Mitomi H, Torigoe T, Takagi T, Suehara Y, Okubo T, Kaneko K and Yao T: Malignant granular cell tumor with an unusually long clinical course: An autopsy case with review of literature. *J Cancer Sci Ther* 4: 260-263, 2012.
14. Papachristou DJ, Palekar A, Surti U, Cieply K, McGough RL and Rao UN: Malignant granular cell tumor of the ulnar nerve with novel cytogenetic and molecular genetic findings. *Cancer Genet Cytogenet* 191: 46-50, 2009.
15. Di Tommaso L, Magrini E, Consales A, Poppi M, Pasquinelli G, Dorji T, Benedetti G and Baccarini P: Malignant granular cell tumor of the lateral femoral cutaneous nerve: Report of a case with cytogenetic analysis. *Hum Pathol* 33: 1237-1240, 2002.
16. Dubbink HJ, Bakels H, Post E, Zwarthoff EC and Verdijk RM: *TERT* promoter mutations and BRAF mutations are rare in sporadic, and *TERT* promoter mutations are absent in NF1-related malignant peripheral nerve sheath tumors. *J Neurooncol* 120: 267-272, 2104.
17. Griewank KG, Schilling B, Murali R, Bielefeld N, Schwamborn M, Sucker A, Zimmer L, Hillen U, Schaller J, Brenn T, *et al*: *TERT* promoter mutations are frequent in atypical fibroxanthomas and pleomorphic dermal sarcomas. *Mod Pathol* 27: 502-508, 2014.